Protective effect of N(G)-monomethyl-L-arginine against hypotension inducted by combined tumour necrosis factor-α and whole body hyperthermia in rats

International Journal of Hyperthermia

Volumn 12, Issue 5, 1996, Pages 617-634

  Makino, M ^a,d   Lodato, R F ^a   Stephens, L C ^b   Strebel, F R ^a   Jenkins, G ^a   Ohno, S ^a,e   Sakaguchi, Y ^a,e   Kostergaard, J ^c   Tomasovic, S P ^c   Bull, J M C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Section of Veterinary Pathology   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d TOTTORI UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

N(G) monomethyl L arginine; Tumour necrosis factor; Whole body hyperthermia

Indexed keywords

CARBOPLATIN; N(G) METHYLARGININE; TUMOR NECROSIS FACTOR ALPHA; ENZYME INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HYPERTHERMIC THERAPY; HYPOTENSION; INTESTINE MUCOSA; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; RAT; TOXICITY; TREATMENT OUTCOME; ANIMAL; BLOOD PRESSURE; CYTOCHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEVER; FISCHER 344 RAT; HEART RATE; METABOLISM;

ANIMALS; BLOOD PRESSURE; CARBOPLATIN; ENZYME INHIBITORS; FEMALE; FEVER; HEART RATE; HISTOCYTOCHEMISTRY; HYPOTENSION; INTESTINAL MUCOSA; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; RATS; RATS, INBRED F344; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10244238899     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.3109/02656739609027670     Document Type: Article

References (39)

1. G-methylarginine, an inhibitor of endothelium-derived nitrix oxide synthesis, is a potent pressor agent in the guinea pig; Does nitric oxide regular blood pressure in vivo? Biochemical and Biophysical Research Communications, 160, 881-886.
2. BABA, H., STEPHENS, L. C., STREBEL, F. R., SIDDICK, Z. H., NEWMAN, R. A., OHNO, S., and BULL, J. M. C., 1991, Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia. Cancer Research, 51, 3568-3577.
3. G-monomethyl-L-arginine inhibits endotoxin-induced nitrite/nitrate biosynthesis while promoting hepatic damage. Journal of Leukocyte Biology, 48, 565-569.
4. BULL, J. M., LEES, D., SCHUETTE, W., SCHUETTE, W., WHANG-PENG, J., SMITH, R., BYNUM, G., ATKINS, R., GOTDIENER, J. S., GRALNICK, H. R., SHAWKER, T. H., and DELVITA, V. T., 1979, Whole body hyperthermia: a phase-I trial of a potential adjuvant to chemotherapy. Annals of Internal Medicine, 90, 317-323.
5. CARSWELL, E. A., OLD, L. J., KASSEL, R. L., GREEN, S., FIORE, N., and WILLIAMSON, B., 1975, An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy Science of USA, 72, 3666-3670.
6. CREAVEN, P. J., PLAGER, J. E., DUPREE, S., HUBEN, R. P., TAKITA, H., MITTELMAN, A., and PROEFROCK, A., 1987, Phase I clinical trial of recombinant human tumour necrosis factor. Cancer Chemotherapy Pharmacology, 20, 137-144.
7. EDDY, H. A., 1980, Alteration in tumor microvasculature during hyperthermia . Radiology, 137, 515-521.
8. HAUSER, G. J., MCINTOSH, J. K., TRAVIS, W. D., and ROSENBERG, S. A., 1990, Manipulation of oxygen radical-scavenging capacity in mice laters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy. Cancer Research, 50, 3503-3508.
9. HIBBS, J. B., TAINTOR, R. R., VAVRIN, Z., and RACHLIN, E., 1988, Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochemical and Biophysical Research Communications, 157, 87-94.
10. KALLINOWSKI, F., SCHAEFER, C., TYLER, G., and VAUPEL, P., 1989, In vivo targets of recombinant human tumour necrosis factor-α: blood flow, oxygen consumption and growth of isotransplanted rat tumours, British Journal of Cancer, 60, 555-560.
11. KETTELHUT, I. C., FIERS W., and GOLDBERG, A. L., 1987, The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proceedings of the National Academy Science of USA, 84, 4273-4277.
12. KHOKHAR, A. R., LUMETTA, G., and DORAN, S. L., 1988, A convenient method for the preparation of anti-tumour carboxylato (1,2-diaminocyclohexane)-platinum- (II) complexes. Inorganica Chimica Acta, 151, 87-88.
13. G-Methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proceedings of the National Academy Science of USA, 87, 3629-3632.
14. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochemical and Biophysical Research Communications, 172, 1132-1138.
15. KILBOURN, R. G. and GRIFFITH, O. W., 1992a, Overproduction of nitric oxide in cytokine-mediated and septic shock. Journal of National Cancer Institute, 84, 827-831.
16. G-amino-L-arginine. Journal of National Cancer Institute, 84, 1008-1016.
17. KIM, Y. D., LAKE, C. R., LEES, D. E., SCHUETTE, W. H., BULL, J. M., WEISE, V., and KOPIN, I., 1979, Hemodynamic and plasma catecholamine responses to hyperthermic cancer therapy in humans. American Journal of Physiology, 237, H570-H574.
18. LARKIN, J. M., EDWARDS, W. S., SMITH, D. E., and CLARKE, P. J., 1977, Systemic thermotherapy: Description of a method and physiologic tolerance in clinical subjects. Cancer, 40, 3155-3159.
19. LI, L., KILBOURN, R. G., ADAMS, J., and FILDLER, I. J., 1991, Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Research, 51, 2531-2535.
20. 2 consumption and cardiac output during normobaric hyperoxia in conscious dogs. Journal of Applied Physiology, 67, 1551-1559.
21. MAETA, M., KOGA, S., SHIMIZU, N., KANAYAMA, H., HAMAZOE, R., KARINO, T., YAMANE, T., and ODA, M., 1984, Effect of extracorporeally induced total body hyperthermia for cancer on cardiovascular function. Japanese Heart Journal, 25, 993-1000.
22. MALIK, S. and BALKWILL, F. R., 1992, Antiproliferative and antitumor activity of TNF in vitro and in vivo. Tumor Necrosis Factors, 1992, edited by B. B. Aggarwal and K. H. Vilce (New York: Marcel Dekker, pp. 239-268.
23. NAVA, E., PALMER, R. M and MONCADA, S., 1991, Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet, 338, 1555-1557.
24. OHNO, S., SIDDIK, Z. H., STREBEL, F. R., STEPHANS, L. C., SIDDIK, Z. H., KLOSTERGAARD, J., TOMASOVIC, S. P., KHOKHAR, A. R., and BULL, J. M. C., 1992, Increased therapeutic efficacy induced by tumor necrosis factor α combined with platinum complexes and whole body hyperthermia in rats. Cancer Research, 52, 4096-4101.
25. PAGE, R. L., MEYER, R. E., THRALL, D. E., and DEWHIRST, M. W., 1987, Cardiovascular and metabolic response of tumour-bearing dogs to whole body hyperthermia. International Journal of Hyperthermia, 6, 513-525.
26. PALMER, R. M. J., FERRIGE, A. G., and MONCADA, S., 1987, Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 327, 524-526.
27. PALMER, R. M. J., REES, D. D., ASHTON, D. S., and MONCADA, S., 1988, L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochemical and Biophysical Research Communications, 153, 1251-1256.
28. PETROS, A., BENNETT, D., and VALLANCE, P., 1991, Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet, 338, 1557-1558.
29. REES, D. D., PALMER, R. M. J., and MONCADA, S., 1989, Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proceedings of the National Academy Science of USA, 86, 3375-3378.
30. ROTHSTEIN, J. L., and SCHREIBER, H., 1988, Tissue damage caused by TNF and complement. Tomor Necrosis Factors, 1992, edited by B. B. Aggarwal and K. J. Vilce (New York: Marcel Dekker, Inc), pp. 453-481.
31. SCHIRMER, W. J., SCHIRMER, J. M., and FRY, D. E., 1989, Recombinant human tumor necrosis factor produced hemodynamic changes characteristic of sepsis and endotoxemia. Archives of Surgery, 124, 445-448.
32. STRICKER, E. M., 1971, Evaporative cooling in the rat: Interaction with heat loss from the tail. Quarterly Journal of Experimental Physiology, 56, 231-241.
33. TRACY, K. J. BEUTLER, B., LOWRY, S. F., MERRYWEATHER, J., WOLPE, S., MILSARK, I. W., HARIRI, R. J., FAHEY, T. J., ZENTELLA, A., ALBERT, J. D., SHIRES, G. T., and CERAMI, A., 1986, Shock and tissue injury induced by recombinant human cachectin. Science, 324, 470-474.
34. TRACEY, K. H. LOERY, S. F., FAHEY, T. J., ALBERT, J. D., FONG, Y., HESSE, D., BEUTLER, B., MANOGUE K. R., CALVANO, S., WEI, H., CERAMI, A., and SHIRES, G. T., 1987, Cachectin/ Tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surgery, Gynecology and Obstetrics, 164, 415-422.
35. TURNER, C. R., ESSER, K. M., WHEELDON, E. B., SLIVJAK, M., and SMITH, E. F., 1989, Cardiovascular and pulmonary effects of human recombinant tumor necrosis factor in the conscious rat. Circulatory Shock, 28, 369-384.
36. WATANABE, N., NIITSU, Y., UMENO, H., SONE, H., NEDA, H., YAMAUCHI, N., MAEDA, M., and URUSHIZAKI, I., 1988a, Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Research, 48, 650-653.
37. WATANABE, N., NIITSU, Y., UMENO, H., KURIYAMA, H., NEDA, H., YAMAUCHI, N., MAEDA, M., and URUSHIZAKI, I., 1988b, Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Research, 48, 2179-2183.
38. WONDERGEM, J., BULGER, R. E., STREBEL, F. R., NEWMAN, R. A., TRAVIS, E. L., STEPHANS, L. C., and BULL, J. M. C., 1988a, Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Research, 48, 440-446.
39. WONDERGEM, J., STREBEL, F. R., SIDDIK, Z. H., NEWMAN, R. A., and BULL, J. M. C., 1988b, The effects of anaesthetics on cisplatinum-induced toxicity at normal temperatures and during whole-body hyperthermia: the influence of NaCl concentration of the vehicle. International Journal of Hyperthermia, 4, 643-654.